Skip to main content
Premium Trial:

Request an Annual Quote

Celera Extends License for Nanogen's MGB Technology for Dx Development

NEW YORK (GenomeWeb News) – Celera has extended an existing licensing agreement for Nanogen's Minor Groove Binder technology that will enable it to develop additional diagnostic products, Nanogen said today.
 
Celera originally licensed the MGB technology in 2004 from Epoch Biosciences to develop hepatitis C genotyping products for patient management, monitoring, and treatment. Nanogen acquired Epoch for $97 million later that year.
 
Under the expanded agreement, Celera will use the MGB technology to develop in vitro diagnostic products for cardiovascular and oncological applications, Nanogen said.
 
Nanogen said that Celera will provide an upfront license fee, milestone and anniversary fees throughout development, and a royalty on sales of the diagnostic products.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.